|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2001-4-30
|
|
pubmed:abstractText |
Thalidomide is currently used as a very promising drug in patients with recurrent multiple myeloma or those refractory to chemotherapy. Literature data show prolonged survival in patients with advanced multiple myeloma treated with thalidomide but the optimal time and dose of thalidomide treatment remain to be established.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0390-6078
|
|
pubmed:author |
pubmed-author:CiepnuchHH,
pubmed-author:DmoszynskaAA,
pubmed-author:HellmannAA,
pubmed-author:HusMM,
pubmed-author:JawniakDD,
pubmed-author:LegiecWW,
pubmed-author:MankaDD,
pubmed-author:Polish Multiple Myeloma Study Group,
pubmed-author:SkotnickiAA,
pubmed-author:Soroka-WojtaszkoMM,
pubmed-author:Wolska-SmolenTT
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
86
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
404-8
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11325647-Adult,
pubmed-meshheading:11325647-Aged,
pubmed-meshheading:11325647-Angiogenesis Inhibitors,
pubmed-meshheading:11325647-Drug Resistance, Neoplasm,
pubmed-meshheading:11325647-Female,
pubmed-meshheading:11325647-Humans,
pubmed-meshheading:11325647-Male,
pubmed-meshheading:11325647-Middle Aged,
pubmed-meshheading:11325647-Multiple Myeloma,
pubmed-meshheading:11325647-Recurrence,
pubmed-meshheading:11325647-Thalidomide,
pubmed-meshheading:11325647-Treatment Outcome
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Thalidomide treatment of resistant or relapsed multiple myeloma patients.
|
|
pubmed:affiliation |
Department of Hematology University Medical School, Lublin, Poland.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
